The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, highlighted important new developments in the management of early and metastatic breast cancer. At a satellite event on May 31, Drs. Rohit and Rahul Gosain—the Oncology Brothers—reviewed key clinical trials in breast cancer in conversation with 2 breast oncology leaders: Dr. Komal Jhaveri from Memorial Sloan

Transitions in lung cancer treatment drove the discussion at an Oncology Brothers Advancements in Oncology event held alongside ASCO 2025. Narjust Florez, MD, of Dana-Farber Cancer Institute, and Sandip Patel, MD, of UC San Diego Health, joined Rahul Gosain, MD, to focus on precision medicine and patient-centered care. These leading oncologists emphasized the importance of individualized care, mul

Leading voices in GI oncology joined Rahul Gosain, MD, MBA, and Rohit Gosain, MD—the Oncology Brothers—at an Advancements in Oncology (AIO) live event held alongside the 2025 ASCO Annual Meeting in Chicago. Tanios Bekaii-Saab, MD, of Mayo Clinic, and Namrata Vijayvergia, MD, of Fox Chase Cancer Center, offered their perspectives on integrating emerging data into clinical care across colorectal

ASCO 2025 featured several major developments in gastrointestinal (GI) oncology, showcasing potentially practice-changing findings across 4 key trials: BREAKWATER, MATTERHORN, ATOMIC, and CHALLENGE.

Beamion LUNG-1 shows zongertinib’s 71% response rate and strong safety in HER2-mutant NSCLC, offering a hopeful alternative to T-DXd for community oncologists.

With the 2025 ASCO Annual Meeting just around the corner, including over 20 sessions centered on breast cancer, it’s a good time to review recently reported updates in this space. At the latest San Antonio Breast Cancer Conference (SABCS), held in December 2024, several presentations focused on breast cancer brain metastasis (BCBM) and treatment of neurotoxicity.